EMERGENT BIOSOLUTIONS INC. Form 8-K (Jan. 13, 2020)

Summary

A Form 8-K current report of Emergent BioSolutions Inc., dated January 13, 2020 and signed by Richard S. Lindahl, Executive Vice President, Chief Financial Officer and Treasurer. Under Item 2.02 the company announced preliminary unaudited financial results for 2019 and guidance for 2020, with the press release furnished as Exhibit 99.1. Selected sections of a corporate slide deck (Exhibit 99.2) are incorporated by reference. Under Item 7.01 company representatives were to present those slides at the J.P. Morgan Healthcare Conference in San Francisco during the week of January 13, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2020

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware | 001-33137 | 14-1902018
(State or other jurisdiction | (Commission File Number) | (IRS Employer
of incorporation) | Identification No.)

400 Professional Drive , Suite 400 ,

Gaithersburg , Maryland 20879

(Address of principal executive offices, including zip code)

( 240 ) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, Par Value $0.001 per share | EBS | New York Stock Exchange

Item 2.02 Results of Operations and Financial Condition .

On January 13, 2020, Emergent BioSolutions Inc. announced preliminary unaudited financial results for 2019 and guidance for 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In addition, the sections entitled “Who we are today,” “Consistent diversified revenue growth…,” “…Driving strong profitability,” “2019 financial goals,” “Reconciliation of Net Income to Adjusted Net Income” and “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” of the corporate slide deck furnished as Exhibit 99.2 are incorporated herein by reference.

Item 7.01. Regulation FD Disclosure

During the week of January 13, 2020, representatives of the company will be attending meetings with investors, analysts and others at the J.P. Morgan Healthcare Conference in San Francisco, California and these company representatives will present the slides attached as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits .

(d) Exhibits.

Exhibit No. | Description
99.1 | Press release, dated January 13, 2020.
99.2 | Corporate slide deck, dated January 14, 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EMERGENT BIOSOLUTIONS INC.
Dated: January 13, 2020 | By: | /s/ RICHARD S. LINDAHL
Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

File and source

File

SEC_EBS_8-K_filed2020-01-13_0001367644-20-000002.htm

Size

44,206 bytes

SHA-256

a53ada17ff08e4b3b196ca37e79647eabebbb3551de4a1dba3c6a53fe96f9772

Our copy

SEC_EBS_8-K_filed2020-01-13_0001367644-20-000002.htm

Original

www.sec.gov